Insider · CIK 0001139306
Gabriele M Cerrone
Files at TLSA (Tiziana Life Sciences Ltd), OKYO (OKYO Pharma Ltd), ACUT (Accustem Sciences Inc.). First filing Jan 3, 2025, latest Jun 16, 2025.
Gabriele M Cerrone files SEC Form 4 as director and 10% owner at ACUT (Accustem Sciences Inc.), and also at TLSA (Tiziana Life Sciences Ltd), OKYO (OKYO Pharma Ltd). Since Jan 3, 2025, Gabriele M Cerrone has reported 5 open-market buys worth $163k and 0 open-market sells worth $0, the latest filed on Jun 16, 2025.
A track record needs three past buys with six months of prices behind them; Gabriele M Cerrone has 0, so none is measured yet.
The newest scored trade: bought $2,440 of ACUT on Jun 13, 2025, filed Jun 16, 2025, scored 15 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ACUT: Accustem Sciences Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | ACUTbuy Accustem Sciences Inc. | $2,440 2,400 shares | +0% | +395% from low0% from high | |
| 15Weak | ACUTbuy Accustem Sciences Inc. | $18k 37,196 shares | +1% | +173% from low-11% from high | |
| 20Weak | ACUTbuy Accustem Sciences Inc. | $25k 38,000 shares | +1% | +182% from low-8% from high | |
| 29Weak | ACUTbuy Accustem Sciences Inc. | $78k 152,802 shares | +3% | +116% from low-12% from high | |
| 21Weak | ACUTbuy Accustem Sciences Inc. | $38k 100,000 shares | +2% | - |
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | TLSA Tiziana Life Sciences Ltd | AGrant or award COMMON STOCKindirect: Via Panetta Partners Limited | +15,000 | $1.11 | $17k | 44,772,230 | Jun 17, 2026 |
| Jun 8, 2026 | OKYO OKYO Pharma Ltd | AGrant or award COMMON STOCKindirect: Via Panetta Partners Limited | +300,000 | $1.72 | $516k | 10,826,416 | Jun 10, 2026 |
| Jun 13, 2025 | ACUT Accustem Sciences Inc. | POpen-market purchase Common Stockindirect: Via Panetta Partners Limited | +2,000 | $1.00 | $2,000 | 6,502,000 | Jun 16, 2025 |
| Jun 13, 2025 | ACUT Accustem Sciences Inc. | POpen-market purchase Common Stockindirect: Via Panetta Partners Limited | +400 | $1.10 | $440 | 6,502,400 | Jun 16, 2025 |
| Jun 11, 2025 | ACUT Accustem Sciences Inc. | POpen-market purchase Common Stockindirect: Via Panetta Partners Limited | +28,205 | $0.39 | $11k | 6,491,009 | Jun 13, 2025 |
| Jun 12, 2025 | ACUT Accustem Sciences Inc. | POpen-market purchase Common Stockindirect: Via Panetta Partners Limited | +8,991 | $0.83 | $7,463 | 6,500,000 | Jun 13, 2025 |
| Apr 8, 2025 | ACUT Accustem Sciences Inc. | POpen-market purchase Common Stockindirect: Via Panetta Partners Limited | +35,000 | $0.67 | $23k | 4,907,759 | Apr 10, 2025 |
| Apr 9, 2025 | ACUT Accustem Sciences Inc. | POpen-market purchase Common Stockindirect: Via Panetta Partners Limited | +3,000 | $0.67 | $2,010 | 4,910,759 | Apr 10, 2025 |
| Mar 18, 2025 | ACUT Accustem Sciences Inc. | POpen-market purchase Common Stockindirect: Via Panetta Partners Limited | +100,000 | $0.45 | $45k | 4,819,957 | Apr 8, 2025 |
| Apr 7, 2025 | ACUT Accustem Sciences Inc. | POpen-market purchase Common Stockindirect: Via Panetta Partners Limited | +17,802 | $0.61 | $11k | 4,837,759 | Apr 8, 2025 |
| Apr 7, 2025 | ACUT Accustem Sciences Inc. | POpen-market purchase Common Stockindirect: Via Panetta Partners Limited | +35,000 | $0.65 | $23k | 4,872,759 | Apr 8, 2025 |
| Dec 31, 2024 | ACUT Accustem Sciences Inc. | POpen-market purchase Common Stockindirect: Via Panetta Partners Limited | +100,000 | $0.38 | $38k | 4,719,957 | Jan 3, 2025 |
Questions about Gabriele M Cerrone
Answered from the filings on this page, as of the latest one.
Is Gabriele M Cerrone buying or selling?
Not in the last 12 months. Gabriele M Cerrone's latest open-market trade on SEC Form 4 was bought $2,440 of ACUT on Jun 13, 2025.
How did Gabriele M Cerrone's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Gabriele M Cerrone has 0.
Where does Gabriele M Cerrone file Form 4?
Gabriele M Cerrone has filed Form 4 at ACUT (Accustem Sciences Inc.); TLSA (Tiziana Life Sciences Ltd); OKYO (OKYO Pharma Ltd). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.